Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo
- PMID: 25878495
- PMCID: PMC4388088
- DOI: 10.2147/IJN.S79367
Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo
Abstract
Active molecular targeting has become an important aspect of nanoparticle development for oncology indications. Here, we describe molecular targeting of iron oxide nanoparticles (IONPs) to the folate receptor alpha (FOLRα) using an engineered antibody fragment (Ffab). Compared to control nanoparticles targeting the non-relevant botulinum toxin, the Ffab-IONP constructs selectively accumulated on FOLRα-overexpressing cancer cells in vitro, where they exhibited the capacity to internalize into intracellular vesicles. Similarly, Ffab-IONPs homed to FOLRα-positive tumors upon intraperitoneal administration in an orthotopic murine xenograft model of ovarian cancer, whereas negative control particles showed no detectable tumor accumulation. Interestingly, Ffab-IONPs built with custom 120 nm nanoparticles exhibited lower in vitro targeting efficiency when compared to those built with commercially sourced 180 nm nanoparticles. In vivo, however, the two Ffab-IONP platforms achieved equivalent tumor homing, although the smaller 120 nm IONPs were more prone to liver sequestration. Overall, the results show that Ffab-mediated targeting of IONPs yields specific, high-level accumulation within cancer cells, and this fact suggests that Ffab-IONPs could have future utility in ovarian cancer diagnostics and therapy.
Keywords: antibody fragment; biodistribution; nanoparticle targeting; ovarian cancer.
Figures








Similar articles
-
Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors.Small. 2014 Feb 12;10(3):544-55. doi: 10.1002/smll.201301593. Epub 2013 Aug 27. Small. 2014. PMID: 24038985 Free PMC article.
-
Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.J Neurooncol. 2015 Aug;124(1):13-22. doi: 10.1007/s11060-015-1807-0. Epub 2015 May 17. J Neurooncol. 2015. PMID: 25981803 Free PMC article.
-
IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.ACS Nano. 2015 Aug 25;9(8):7976-91. doi: 10.1021/acsnano.5b01288. Epub 2015 Aug 10. ACS Nano. 2015. PMID: 26242412 Free PMC article.
-
Biodistribution and targeting properties of iron oxide nanoparticles for treatments of cancer and iron anemia disease.Nanotoxicology. 2019 Jun;13(5):573-596. doi: 10.1080/17435390.2019.1572809. Epub 2019 Apr 2. Nanotoxicology. 2019. PMID: 30938215 Review.
-
[Development of Molecular Probes Based on Iron Oxide Nanoparticles for in Vivo Magnetic Resonance/Photoacoustic Dual Imaging of Target Molecules in Tumors].Yakugaku Zasshi. 2017;137(1):55-60. doi: 10.1248/yakushi.16-00228. Yakugaku Zasshi. 2017. PMID: 28049896 Review. Japanese.
Cited by
-
The treatment value of IL-1β monoclonal antibody under the targeting location of alpha-methyl-L-tryptophan and superparamagnetic iron oxide nanoparticles in an acute temporal lobe epilepsy model.J Transl Med. 2018 Dec 4;16(1):337. doi: 10.1186/s12967-018-1712-3. J Transl Med. 2018. PMID: 30514296 Free PMC article.
-
Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems.Pharmaceutics. 2017 Oct 14;9(4):46. doi: 10.3390/pharmaceutics9040046. Pharmaceutics. 2017. PMID: 29036899 Free PMC article. Review.
-
Click Chemistry-Based Bioconjugation of Iron Oxide Nanoparticles.Small. 2025 Mar;21(11):e2407883. doi: 10.1002/smll.202407883. Epub 2025 Feb 9. Small. 2025. PMID: 39924809 Free PMC article.
-
A Feasibility Study of Nonlinear Spectroscopic Measurement of Magnetic Nanoparticles Targeted to Cancer Cells.IEEE Trans Biomed Eng. 2017 May;64(5):972-979. doi: 10.1109/TBME.2016.2584241. Epub 2016 Jun 23. IEEE Trans Biomed Eng. 2017. PMID: 27352362 Free PMC article.
-
The Dartmouth Center for Cancer Nanotechnology Excellence: magnetic hyperthermia.Nanomedicine (Lond). 2015;10(11):1685-92. doi: 10.2217/nnm.15.64. Nanomedicine (Lond). 2015. PMID: 26080693 Free PMC article.
References
-
- Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2011, National Cancer Institute. Bethesda, MD: National Cancer Institute; 2014. [Accessed November 27, 2014]. Available from: http://seer.cancer.gov/csr/1975_2011/
-
- Zee Vd. Heating the patient: a promising approach. Annals of Oncology. 2002;13:1173–1184. - PubMed
-
- Moroz P, Jones SK, Gray BN. Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia. 2002;18:267–284. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources